semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Advanced Idiopathic Parkinson's Disease Advanced Parkinson's disease (ie, takes Levodopa (L-DOPA)) Hoehn and Yahr stage score of 2 to 4 Subject has sleep-maintenance insomnia  Significant skin disease that would make transdermal drug use inappropriate Subject received therapy with controlled-release Levodopa (L-DOPA), entacapone or Stalevo® within 28 days prior to the Baseline Visit or has received therapy with Tolcapone Atypical Parkinsonian syndromes Previous diagnosis of Narcolepsy, Sleep Apnoea Syndrome, significant Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD), moderate to severe Restless Legs Syndrome (RLS) or Periodic Limb Movement Disorder
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Urinary Incontinence Nocturia Clinical diagnosis of Parkinson's disease determined by a board-certified neurologist with specialty training in movement disorders ≥ 4 weekly episodes of UI and at least one episode per week associated with feelings of urgency, where urgency is defined as the complaint of a sudden compelling desire to void which is difficult to defer Willingness to attend clinic visits Willingness to keep 7-day bladder diaries throughout the study period  Significant cognitive impairment, as indicated by a Montreal Cognitive Assessment (MoCA) score of < 18 Inability to produce an interpretable 7-day bladder diary at baseline Previous intensive PFME training Clinically significant depression as measured by a Geriatric Depression Scale-Short Form score ≥ 10 which could affect motivation to fully engage in the intervention Use of an indwelling urinary catheter Bladder outlet obstruction defined as having been prescribed in-and-out catheterization in the past 12 months, having a post-void residual urine volume by bladder ultrasound of ≥ 200 mL or a peak voiding flow rate of ≤ 4 mL/min on a void ≥ 125 mL in volume Severe uterine prolapse past the vaginal introitus Poorly controlled diabetes defined by a hemoglobin A1c (HgbA1c) of >8.0% Chronic renal failure and on hemodialysis Poorly controlled congestive heart failure or poorly controlled chronic obstructive pulmonary disease on physical exam
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Parkinson's Disease Idiopathic Parkinson's disease, defined by the UK Brain Bank with a Hoehn and Yahr score of 2 to 4 Treated with levodopa for at least a year and on a stable antiparkinsonian regimen for at least one month Abnormal computerized dynamic posturography (CDP) on screening defined as a composite score below 65 (range 1-100)  Dementia defined by MMSE less than 27 Other medical conditions other than PD affecting balance or gait as determined by the investigators Unable to stand unassisted for 30 minutes Current use of an acetylcholinesterase inhibitors or drugs with known anticholinergic properties Medical or psychiatric co-morbidities that may interfere with compliance or might place subject in danger as determined by the investigators
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Parkinson Disease Clinical diagnosis of Parkinson Disease  Patients with a limitation in the shoulder range of motion necessary to perform pointing movements
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 19.0-85.0,  Movement Disorders (Incl Parkinsonism) Tremor Familial Essential, 1 REM Sleep Behavior Disorder Healthy Control • Age 35-85 Parkinson Disease (PD) Age 35-85 Diagnosis of clinically definite PD made by a movement disorders specialist, with evidence of the following features Presence of bradykinesia and 1 or both of the following: 1. Rest tremor 2. Rigidity Asymmetric Onset Progressive motor symptoms Levodopa responsive Duration at least 1 but not more than 10 years Hoehn and Yahr Stage 1-2 Progressive Supranuclear Palsy (PSP) Age 40-85 Diagnosis of clinically definite PSP, with the following features Gradually progressive disorder Onset after age 39 Supranuclear palsy* and postural instability with falls in the first year of disease onset*  Healthy Control Pregnancy First-degree blood relative affected by PD Neurodegenerative disease History of repeated head injury, encephalitis, brain surgery, stroke, dementia, neuroleptic exposure, or serious medical illness that may interfere with participation. Parkinson Disease (PD) Any that would a healthy control patient Atypical features indicative of a Parkinson-Plus disorder Progressive Supranuclear Palsy (PSP) Any that would a healthy control patient
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Parkinson's Disease Primary Parkinsonism Lewy Body Parkinson's Disease Males or females ≥ 40 years of age Presenting (within the last 3 months) for an initial evaluation to a movement disorders specialist with signs or symptoms suggestive of a movement disorder The subject's signs or symptoms were previously evaluated by a physician who was not a movement disorders specialist during the previous six months Absence of an established clinical movement disorder diagnosis Symptoms mild in intensity, this includes Hoehn & Yahr ≤ 2 (Exceptions are allowed for subjects who meet for Hoehn & Yahr stage 3 due to early onset of postural instability and/or gait impairment out of proportion to his/her other Parkinson signs and symptoms) Montreal Cognitive Assessment (MoCA) score ≥ 22 Can tolerate imaging visit procedures; and Provide written informed consent prior to study entry  Have been referred to the movement disorders clinic primarily for the purpose of disease management (no diagnostic uncertainty exists on the part of the non-specialist or referring physician) Have a previous movement disorder diagnosis given by a movement disorders specialist prior to the time of enrollment Have received a total of more than 90 days treatment with dopaminergic medications, including direct dopamine agonists or precursors (levodopa) or have received a total of more than 180 days treatment with MAO-B inhibitors, amantadine, anticholinergics or primidone or beta-blockers prescribed for treatment of tremor or signs of parkinsonism Have had a sustained and clinically meaningful response to anti-parkinsonian medications Are currently taking or have taken MAO-B inhibitors in the past 4 weeks Have a known CNS structural lesion such as stroke or tumor that likely accounts for their symptoms Have clinically meaningful cognitive impairment or dementia (mild cognitive problems as might be expected in the earliest stages of PD are not exclusionary) Have current clinically significant cardiovascular disease or clinically important abnormalities on screening ECG (including but not limited to QTc > 450 msec) Are currently taking medications that are known to cause QT-prolongation Are currently taking medications with narrow therapeutic windows (e.g. warfarin or other anticoagulant therapies)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-75.0,  Parkinson's Disease Diagnosis of idiopathic Parkinson's disease according to the UK Queen Square Brain Bank Hoehn & Yahr disease stages I-II Age between 30 and 75 years Having insufficient physical activity according to the ACSM guideline for adults, 50-64 years old with a chronic condition Untreated with anti-parkinsonian medication or receiving medication, for less than two years, medication-responsive without fluctuations  Unclear diagnosis with Red Flags Advanced problems in cognitive functioning: Mini Mental State Examination (MMSE)19 score < 24 Serious co-morbidity: neurological or orthopedic disorder that severely affects movement; known by specialist or medical practitioner Pulmonary diseases; known by specialist or medical practitioner Stroke High risk of cardiovascular complications Hypertension (systole >150 and diastole > 100) Diabetes Mellitus; known by specialist or medical practitioner Cardiac valve defect (especially aortic valve stenosis); known by specialist or medical practitioner Cardiac rhythm disorder; known by specialist or medical practitioner
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson's Disease Patients will be eligible for if they have a diagnosis of idiopathic PD The subjects must speak either English or French sufficiently to fill out questionnaires and understand the instructions for dance classes (classes will be bilingual)  Patients who cannot stand for at least 30 min and walk for ≥3 m without an assistive device. 2. Individuals with Hoehn and Yahr stage IV V (severe and nonambulatory) 3. Dementia, defined according to PD dementia as MMSE< 26/30 and ADL impairment secondary to cognitive loss, or inability to understand consent process60 4. Serious hearing and vision problems that could affect the participation in dance classes. 5. Change to dopaminergic therapy over the preceding three months, or changes to antiparkinsonian medication are anticipated during the study protocol 6. Serious medical conditions, including cardiac disease or evidence of musculoskeletal problem which precludes dancing or can be worsened by exercise 7. History of frequent falls, with more than 3 falls in the last 12 months
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 65.0-85.0,  Parkinson´s Disease Patients with Parkinson´s disease both gender on stages 1 and 2,5 of Hoehn e Yahr  depression cognitive impairment deficits of visual acuity Score on Berg Balance Scale under 46
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-99.0,  Parkinson's Disease Parkinsonism Parkinsonian patients with Freezing of Gait or Gait hesitation Must have evidence of bradykinesia ambulating (stride reduction or reduced arm swing) Must have a constant caregiver  No cardiopulmonary contraindications to ambulation, e.g., unstable angina pectoris Severe arthritis Cerebellar or sensory ataxia Recent knee or hip surgery
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 10.0-12.0,  Child Healthy and physically active (as determined by medical and activity questionnaire) 12 years of age Within approximately 2 years of estimated age of peak height velocity (PHV) Minimum aerobic fitness of 35 ml/kg/min as assessed by the McMaster All-out Progressive Continuous Cycling Protocol Having obtained his/her informed assent Having obtained his/her legal representative's informed consent  Post-pubertal Taking any medication Smoker Undergoing medical treatment or investigations Body mass index > 24 Suffer from chronic diseases (with regular intake of drugs, medical history) Vegetarians Vaccination in the last 4 months Any know food allergies or intolerance Pregnancy
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-90.0,  Alzheimer's Disease Mild Cognitive Impairment Frontotemporal Dementia years of age or older (50 years of age or older for frontotemporal dementia patients) Normal memory, mild cognitive impairment (memory loss that does not significantly affect normal daily activities), or clinical diagnosis of Alzheimer's disease or frontotemporal dementia (includes primary progressive aphasia) Right-handed General good physical health  History of stroke or neurological disease (other than Alzheimer's disease or frontotemporal dementia) Seizures or head injury with loss of consciousness within the last five years Ferrous (magnetic) or electronic implants (due to the magnet in the MRI scanner) Claustrophobia
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Parkinson Disease Participants who will be included in the study have probable or definite idiopathic PD (CAPSIT (23)), Hoehn & Yahr stage 2-4 One or more of the following PD-associated motor impairments experienced in the week prior to enrollment (based on history and/or examination): motor fluctuations (end of dose wearing off with hypokinesia and/or levodopa-induced choreiform dyskinesias), tremor, freezing of gait, or frequent falls (≥ 1 per week)  Neurological disorders (other than PD) or orthopedic deficits that, in the investigator's judgement, contribute substantially to impaired movement (e.g. stroke with motor sequelae Essential tremor Severe osteoarthritis) Cognitive impairment sufficiently severe to interfere with informed consent
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Fibromyalgia Primary fibromyalgia as defined by the American College of Rheumatology 2. Age 18-70 years 3. Male or female 4. Competent and willing to give written informed consent  History of head trauma 2. Any significant neurological disorder that may confound neuro-cognitive testing
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-90.0,  Parkinson's Disease Idiopathic Parkinson's disease patient  Patient with Secondary Parkinsonism eg.Drug-induced Parkinsonism, Vascular Parkinsonism, exposure to toxin, Encephalitis 2. Patient with Atypical Parkinsonial Syndromes eg. Parkinson-plus syndrome, Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD) 3. Patient with Heredodegenerative parkinsonism eg. Spinocerebellar ataxias, Wilson's disease, Juvenile Huntington's disease